Search results for "Briakinumab"

showing 1 items of 1 documents

Anti–Interleukin-12 Antibody for Active Crohn's Disease

2004

Crohn's disease is associated with excess cytokine activity mediated by type 1 helper T (Th1) cells. Interleukin-12 is a key cytokine that initiates Th1-mediated inflammatory responses.This double-blind trial evaluated the safety and efficacy of a human monoclonal antibody against interleukin-12 (anti-interleukin-12) in 79 patients with active Crohn's disease. Patients were randomly assigned to receive seven weekly subcutaneous injections of 1 mg or 3 mg of anti-interleukin-12 per kilogram of body weight or placebo, with either a four-week interval between the first and second injection (Cohort 1) or no interruption between the two injections (Cohort 2). Safety was the primary end point, an…

AdultMalemedicine.medical_specialtyColonmedicine.medical_treatmentPlaceboGastroenterologychemistry.chemical_compoundCrohn DiseaseDouble-Blind MethodInternal medicinemedicineClinical endpointBriakinumabHumansAgedAged 80 and overCrohn's diseasebiologybusiness.industryRemission InductionAntibodies MonoclonalGeneral MedicineMiddle Agedmedicine.diseaseInterleukin-12digestive system diseasesCytokinechemistryImmunologyCohortLeukocytes MononuclearInterleukin 12biology.proteinCytokinesFemaleAntibodybusinessNew England Journal of Medicine
researchProduct